Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080017
Chunk: 65

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 65
---
     |             | 9.64 |
| Options granted                         |     |             | 70,904 |     | $         |  14.55 |     |             |    - |
| Balance, June 30, 2025 (Successor)      |     |             | 74,151 |     | $         |  22.67 |     |             | 9.82 |
| Options exercisable as of June 30, 2025 |     |             |  8,413 |     | $         |  77.16 |     |             | 9.61 |

The Company estimated the fair value of the stock options during the
six months ended June 30, 2025 and for the period from February 14, 2024 to June 30, 2024 using Black-Scholes with the following assumptions.

|                          |     | Six Months Ended 
 June 30,         
 2025             |                    |     | February 14, 2024 to June 30, 
 2024                          |                  |
|:-------------------------|:----|:-----------------|-------------------:|:----|:------------------------------|:-----------------|
|                          |     | -Successor       |                    |     | -Successor                    |                  |
| Risk-free interest rate  |     |                  |     3.98% to 4.01% |     |                               | 4.46% to 4.79%   |
| Expected life (in years) |     |                  |                5.0 |     |                               | 5.0 to 6.0       |
| Expected dividend yield  |     |                  |                 -% |     |                               | -%               |
| Expected volatility      |     |                  | 104.54% to 121.09% |     |                               | 143.4% to 153.5% |

There were no stock options granted during the predecessor period from
January 1, 2024 and February 13, 2024.

For the period from February 14, 2024 through June 30, 2024, the Company recorded stock-based compensation expense of $1,485,027, of which $849,952 was related to R&D and $635,075 was related to general and administrative. For the period from January 1, 2024 through February 13, 2024,